
AFRL's portfolio strategy spreads study contracts across five providers (SpaceX, Blue Origin, Sierra Space, Rocket Lab, Anduril) but concentrates flight-demo funding on the two with operational medium-heavy launchers — SpaceX and Rocket Lab. That bifurcation creates a forcing function: study-phase contractors either graduate to funded demos by proving unique capability (Sierra's orbital reentry platform, Anduril's reentry container) or get priced out when AFRL consolidates around flight-proven systems.
Blue Origin now trails SpaceX by an order of magnitude in DoD point-to-point funding — $13M versus SpaceX's $102M Starship contract — which means AFRL is hedging across multiple launchers but betting heaviest on the platform with demonstrated heavy-lift capacity.
The $11.7M increment keeps Blue Origin in the REGAL competition through the next study phase, but without a funded flight demo (REGAL contracts explicitly exclude flight funding), the company faces a 2027 decision point: self-fund a New Glenn cargo demonstration or cede the operational contract to SpaceX and Rocket Lab, both of which have NET 2026 demo flights already contracted.
Has Blue Origin committed internal capital to a self-funded point-to-point demo flight, or is the company waiting for AFRL to transition REGAL from study contracts to funded flight demonstrations?
Strategic intelligence, synthesized daily — with a public track record. Every call graded against what actually happened.